CORDIS - EU research results
CORDIS

Rapid COVID-19 Passive Therapy Response Platform

Project description

Passive immunisation as a strategy to treat the coronavirus infection

Short-lived passive immunisation as anti-COVID-19 therapy is immediately required to flatten the infection curve and to provide time for herd immunity approaches. The strategy requires the exploitation of the extreme heterogeneity of the human anti-viral immune response. Irish company Remedy Biologics has developed a platform to rapidly and simultaneously analyse millions of single antibody-producing immune cells from an individual sample. It presents an opportunity to identify the best antibodies from the immune systems of COVID-19 convalescents to be used in the creation of passive therapeutics for critically ill patients. The EU-funded RapCo-19 project aims to combine novel discovery technologies to create a platform for the rapid identification and production of anti-viral neutralising antibodies against COVID-19.

Objective

The SARS-CoV-2 pandemic requires the most serious and rapid healthcare response seen in modern history. The lag time between the emergence of the pathogen and the implementation of a licensed vaccine still remains an obstacle for prophylactic measures. In addition, how long immunity lasts for following COVID-19 infection is a big unknown. The development of immunity to the currently circulating SARS-CoV2 may not provide sterilising protection against subsequent coronavirus infections. If this were to be confirmed, it would add to the challenge of managing the pandemic.
Short-lived passive immunisation with an anti-COVID-19 therapy is immediately required to treat infected patients and to ‘flatten the infection curve’ and to provide time for ‘herd immunity’ approaches. Devising an effective strategy requires an approach that is designed to exploit the extreme heterogeneity of the human anti-viral immune response.
RemedyBio’s Nanoreactor technology is such a system. It is the result of a 5-year research programme to develop a platform to rapidly and simultaneously analyse millions of single antibody-producing immune cells from an individual sample. In the context of COVID-19, this presents an opportunity to rapidly identify the best antibodies from the immune systems of COVID-19 convalescent patients from which to create a rapid passive therapeutic for those that are critically ill from the virus.
Based on records from 1918/1919, it is plausible for the COVID-19 pandemic to wane in the late spring (in Europe), and come back as a second wave in the winter, which, as was the case in 1918, could be even worse than what we're facing now. COVID-19 is a global health problem and we need to be ready for this. This project is designed to combine novel discovery and delivery technologies to form a platform to rapidly identify, produce and deliver anti-viral neutralising antibodies to COVID-19.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-EIC-SMEInst-2018-2020-3

Funding Scheme

SME - SME instrument

Coordinator

REMEDY BIOLOGICS LIMITED
Net EU contribution
€ 2 500 000,00
Address
76 RACEHILL PARK RACEHILL MANOR
A84R970 ASHBOURNE CO MEATH
Ireland

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 4 500 000,00